Walder Wyss has advised Sulzer in this transaction.
Sulzer Ltd announced the intention to spin-off its Applicator Systems (APS) division through a 1:1 share split.
The listing of APS on the Swiss Exchange (SIX) is planned for late Q3 or early Q4. Upon market introduction, APS will be renamed medmix and its listing will be combined with a share capital increase by medmix in the amount of CHF 200-300m without subscription rights for existing shareholders. The capital increase is expected to fund organic and inorganic growth, increase trading liquidity through a higher free float and introduce new, healthcare-focused investors to medmix.
Sulzer is a global leader in fluid engineering. They specialize in pumping, agitation, mixing and separation technologies for fluids of all types.
The Walder Wyss team was lead by Urs Schenker (Senior Counsel, Transactions/M&A) and Dominik Hohler (Picture – Partner, Transactions/M&A) and further included Theodor Härtsch (Partner, Transactions/Finance), Thomas Meister (Partner, Tax), Janine Corti (Counsel, Tax), Angela Kummer (Associate, Transactions/M&A), Etienne Trandafir (Associate, Transactions/Finance) and Thomas Nagel (Associate, Transactions/Finance).
Involved fees earner: Janine Corti – Walder Wyss Ltd.; Theodor Härtsch – Walder Wyss Ltd.; Dominik Hohler – Walder Wyss Ltd.; Angela Kummer – Walder Wyss Ltd.; Thomas Meister – Walder Wyss Ltd.; Thomas Nagel – Walder Wyss Ltd.; Urs Schenker – Walder Wyss Ltd.; Etienne Trandafir – Walder Wyss Ltd.;
Law Firms: Walder Wyss Ltd.;